It is well established that canonical NF-κB plays essential roles in immune response, thus long-term use of NF-κB inhibitor could result in immunodeficiency, so NF-κB inhibitor for cancer therapy should be used in a short period of time. The gene discussed is NFKB1; the disease is immunodeficiency disease.